Addendum
Finerenone (heart failure with LVEF ≥ 40%) – Addendum to Project A26-42
Report documents
-
Addendum
Finerenone (heart failure with LVEF ≥ 40%) – Addendum to Project A26-42
Dossier assessment
Indication:
Adults with symptomatic chronic heart failure with left ventricular ejection fraction ≥40%
Result of dossier assessment:
Unchanged after addendum: added benefit not proven
Additional information
Federal Joint Committee (GBA)
15-10-2026 A G-BA decision was published.
GBA documents on this decision
Project details
- Project no.
- A26-111
- Commission
- Commission awarded on 08.09.2026 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Heart and circulation
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
- DOI
https://doi.org/10.60584/A26-111
Connected Projects
-
Dossier assessment
Finerenone (heart failure with LVEF ≥ 40%) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed